Compile Data Set for Download or QSAR
Report error Found 200 Enz. Inhib. hit(s) with Target = 'Epidermal growth factor receptor [L858R,C797S]'
TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717188(3-[3-(4-fluorophenyl)-4-(6- phenyl-7H-pyrrolo[2,3-...)
Affinity DataIC50: 0.0990nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717208(3-[4-(4-fluorophenyl)-5-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.111nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717197(3-[4-(4-fluorophenyl)-5-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.141nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717189(3-[3-(4-fluorophenyl)-4-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.152nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717282(N-{2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]py...)
Affinity DataIC50: 0.160nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717273(2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717212(3-[3-(4-fluorophenyl)-4-{6-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.212nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717198(3-[3-(4-fluorophenyl)-4-{6-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.242nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717234(4-{3-(4-fluorophenyl)-1-[3- (methanesulfonyl)propy...)
Affinity DataIC50: 0.247nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717186(3-[3-(4-fluorophenyl)-4-(8- phenyl-9H-purin-6-yl)-...)
Affinity DataIC50: 0.253nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717244(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.263nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717194(3-[3-(4-fluorophenyl)-4-{8-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.270nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717192(3-[3-(4-fluorophenyl)-4-{2-[4- (4-methylpiperazin-...)
Affinity DataIC50: 0.272nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717231(3-{2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]py...)
Affinity DataIC50: 0.307nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717219(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.327nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717249(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.328nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717276((3S)-3-{[3-(4-fluorophenyl)-4- (6-phenylfuro[2,3-d...)
Affinity DataIC50: 0.330nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717237(1-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.349nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717281(4-{3-(4-fluorophenyl)-1-[(3S)-1- (methanesulfonyl)...)
Affinity DataIC50: 0.350nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717270(4-{3-(4-fluorophenyl)-1-[(3S)- oxolan-3-yl]-1H-pyr...)
Affinity DataIC50: 0.370nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717295(4-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.370nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717268(4-{3-(4-fluorophenyl)-1-[1- (methanesulfonyl)pyrro...)
Affinity DataIC50: 0.380nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717225(1-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.389nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717222((1r,3r)-3-{[3-(4-fluorophenyl)-4- (6-phenylfuro[2,...)
Affinity DataIC50: 0.390nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717275((3R)-3-{[3-(4-fluorophenyl)-4- (6-phenylfuro[2,3-d...)
Affinity DataIC50: 0.390nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717280(4-{3-(4-fluorophenyl)-1-[(3R)-1- (methanesulfonyl)...)
Affinity DataIC50: 0.390nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717227(4-[3-(4-fluorophenyl)-1- (2H3)methyl-1H-pyrazol-4-...)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717288(1-[3-(2-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717294(3-{[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyri...)
Affinity DataIC50: 0.410nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717217(4-{3-(4-fluorophenyl)-1-[2- (methanesulfonyl)ethyl...)
Affinity DataIC50: 0.434nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717285(2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.450nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717290(2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.450nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717248(4-{3-(4-fluorophenyl)-1- [(oxetan-2-yl)methyl]-1H-...)
Affinity DataIC50: 0.452nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717232(3-{[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyri...)
Affinity DataIC50: 0.462nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717296(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.470nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717242(4-[3-(4-fluorophenyl)-1-methyl- 1H-pyrazol-4-yl]-6...)
Affinity DataIC50: 0.474nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717257(2,2-difluoro-3-[3-(4- fluorophenyl)-4-(6- phenylfu...)
Affinity DataIC50: 0.480nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717269(4-{3-(4-fluorophenyl)-1-[(3R)- oxolan-3-yl]-1H-pyr...)
Affinity DataIC50: 0.510nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717220(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.518nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717190(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.521nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717210(4-[3-(4-fluorophenyl)-1-(oxetan- 3-yl)-1H-pyrazol-...)
Affinity DataIC50: 0.521nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717239(4-[3-(4-fluorophenyl)-1H- pyrazol-4-yl]-6-phenylfu...)
Affinity DataIC50: 0.526nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717221((1s,3s)-3-{[3-(4-fluorophenyl)- 4-(6-phenylfuro[2,...)
Affinity DataIC50: 0.527nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717241(4-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.527nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717297(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.560nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717264(4-[3-(4-fluorophenyl)-1-(oxolan- 3-yl)-1H-pyrazol-...)
Affinity DataIC50: 0.580nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717226(4-{3-(4-fluorophenyl)-1- [(oxetan-3-yl)methyl]-1H-...)
Affinity DataIC50: 0.594nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM727131(US20250092017, Compound H12)
Affinity DataIC50: 0.600nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/2/2020
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717240(3-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.601nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,C797S](Human)
Oric Pharmaceuticals

US Patent
LigandPNGBDBM717229(2-[3-(4-fluorophenyl)-4-(6- phenylfuro[2,3-d]pyrim...)
Affinity DataIC50: 0.635nMAssay Description:The inhibitory activity of the compounds disclosed herein were measured in a biochemical assay utilizing a recombinant human EGFR L858R/C797S double ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 200 total ) | Next | Last >>
Jump to: